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ABSTRACT  
A key focus in current cancer research is the discovery of cancer biomarkers that allow earlier detection 
with high accuracy and lower costs for both patients and hospitals. Blood samples have long been used 
as a health status indicator, but DNA methylation signatures in blood have not been fully appreciated in 
cancer research. Historically, analysis of cancer has been conducted directly with the patient’s tumor or 
related tissues. Such analyses allow physicians to diagnose a patient’s health and cancer status; 
however, physicians must observe certain symptoms that prompt them to use biopsies or imaging to 
verify the diagnosis. This is a post-hoc approach. Our study will focus on epigenetic information for 
cancer detection, specifically information about DNA methylation in human peripheral blood samples in 
cancer discordant monozygotic twin-pairs. This information might be able to help us detect cancer much 
earlier, before the first symptom appears. Several other types of epigenetic data can also be used, but 
here we demonstrate the potential of blood DNA methylation data as a biomarker for pan-cancer using 
SAS® 9.3 and SAS® EM. We report that 55 methylation CpG sites measurable in blood samples can be 
used as biomarkers for early cancer detection and classification. 
INTRODUCTION  
Cancer has slowly replaced heart disease and become the number one leading cause of death in the 
United States as of early 2014. The world-wide cancer incidence rate is still increasing; thus, early 
detection through the use of biomarker analysis is a key focus in current cancer research. Two criteria of 
interest are performance—sensitivity, specificity and predictive value, and accessibility—that is, low cost 
and easy access without complicated surgeries (Hartwell et al. 2006). Blood is one of the most abundant 
tissues in the human body, and the process of obtaining blood samples is simple and routine. Blood 
samples have long been used as a health status indicator, but DNA methylation signatures in blood have 
not been fully appreciated in cancer research.  
Cancer diagnoses have typically involved analyses conducted directly on tumor or otherwise cancerous 
tissue. Thus, to determine a patient’s cancer status, physicians have needed to observe certain 
symptoms, then use either biopsy or imaging to verify the diagnosis. If blood samples can be used 
instead of these more invasive techniques, we may be able to detect cancer much earlier, potentially 
even before the first symptom appears. Such an analysis may be possible by examining epigenetic 
features (patterns) present in blood. 
Waddington coined the term “epigenetics” in the 1950’s. He defined it as changes in phenotype (cellular 
level), without changes in genotype (DNA level). We now understand that epigenetic mechanisms 
manipulate gene expression patterns without altering the DNA sequence through several known modes, 
including DNA methylation, histone modification, and chromatin remodeling (Stunnenberg and Hirst 
2016). In the work described here, we have focused on DNA methylation.  
Our understanding of how DNA methylation changes during cellular differentiation, normal development 
and how it relates to other epigenetic mechanisms remains limited. Methylation can only happen on one 
of the four DNA bases, cytosine, to form 5-methylcytosine. Methylation often occurs at CpG sites, where a 
cytosine nucleotide is followed by a guanine nucleotide in the 5’ to 3’ direction(Baylin 2005). CpG islands 
are regions with a high frequency of CpG sites, typically 300–3000 base pairs in length for humans. About 
70% of human promoter regions (proximal promoters) have a high CpG content (Deaton and Bird 2011), 
thus methylation of these regions plays an important role in regulation of gene expression. Methylation 
signatures may differ among tissues and between normal and abnormal cells within the same individual. 
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Aberrant methylation patterns are associated with a number of diseases, age, and environmental factors 
such as smoking or drug abuse (Bjornsson 2008). Therefore, methylation status is a potential candidate 
as a cancer biomarker. Epigenetic sequencing could potentially provide more direct information on 
disease status; however, the data from this method share the same notorious properties as other 
genomic methods: multimodality and high dimensionality (Laird, 2010). More often than not, only a small 
portion of these biomarker features are studied and utilized for disease detection.  
 
Figure 1. Methylation at the cellular level. DNA methylation is essential for normal development and has been 
implicated in many pathologies, including cancers. One of the 4 bases in DNA, cytosine, undergoes 
methylation at its carbon-5 position. At the organism level, methylation play important roles in imprinting, 
development, cellular pluripotency, pluripotency differentiation, oncogenesis, etc. 
Many biological features are candidates for use as biomarkers, but the key aspects characterizing ideal 
biomarkers are high accuracy, low rate of false negatives, and easy accessibility. Blood is a tissue type 
that is a good source of biomarkers. Blood is one of the most abundant and accessible tissues in the 
human body, and the methylation signatures (epigenetic information) found in blood samples provide rich 
information and demonstrate the capability to differentiate cancer status.  
DNA methylation signatures in blood have been associated with breast, colon, bladder, and ovarian 
cancers. To the best of our knowledge, only a limited number of studies have attempted to identify 
epigenetic biomarkers associated with pan-cancer (cancer of multiple organs), and none have 
approached this problem from a statistical perspective(Esteller 2009). Through identifying malignancy-
associated DNA methylation changes in blood, we propose a statistical approach/pipeline to explore the 
potential of blood DNA methylation as a biomarker for pan-cancer.  
METHODS 
DATASETS 
Epigenome-wide DNA methylation profile data were curated by the International Human Epigenome 
Consortium (IHEC) and are publicly accessible from Gene Expression Omnibus (GEO) (Barrett et al. 
2013). IHEC allows us to easily select epigenetic data based on consortium, tissue, and assay type. The 
GEO accession code for the data used for this study is GSE89093; this dataset consists of 92 methylation 
profiles from the HumanMethylation450 BeadChip (450k) platform. Each profile comprises 453,627 
methylation sites. The methylation profile provides a functional assessment by evaluating the plasma 
levels of methionine, cysteine, SAM, SAH, homocysteine and cystathionine. The dataset has been 
normalized at single CpG resolution as beta values with a numerical range between 0 (unmethylated) and 
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1 (methylated); the full dataset can be accessed at GEO website.1 Beta values were obtained from the 
ratio of signal intensity from the methylated probes over the sum of signal intensity from both 
unmethylated and methylated probes (Roos et al. 2016).  
DATA COLLECTION 
Genome-wide peripheral blood DNA methylation profiling (study data) samples were collected from the 
National Cancer Registry at the Office for National Statistics (ONS) for twin-pairs registered with the 
TwinsUK Adult Twin Registry. The participants were 46 adult female monozygotic twin-pairs; samples 
obtained at the same time point, from 41 healthy female participants (not diagnosed with any cancer) 
paired with their monozygotic (MZ) co-twin who were diagnosed with cancer within a five-year window. 
Five extra pairs with a co-twin diagnosed with cancer 5 to 11 years prior to the blood sampling time point 
were also included. A total of 8 types of cancers were included this study; their distribution is included in 
Figure 2. 
 
Figure 2. Cancer typing distribution. Eight common types of cancer were present among 41 participants: 
breast, cervix, colon, ovary, pancreas, skin, thyroid, and uterine cancers. However, due to the limited sample 
size, the cancer types are not evenly distributed, with most cases breast and colon cancers. 
DATA CLEANING/VALIDATION 
To analyze the data with SAS® and SAS® EM, the raw data needed to be reformatted. The feature 
dimension of the data was rather large: 453,627 features (columns) from 92 observations (rows). First, 
the responsive variable column was concatenated to the data. Information from the metadata 
accompanied the original data and indicated the disease status; cancer or healthy. We also included data 
cleaning steps, including transformation.  
To validate the data, we used SAS® PROC UNIVARIATE to generate statistics: (1) moments, (2) basic 
measures of location and variability, (3) tests for location, (4) quantiles, (5) extreme observations. The 
data were then ready for the next step of analysis. 
TRAINING-TESTING DATA SPLITING 
Since the goal of this analysis was to identify potential biomarkers, narrowing 453,627 candidates to only 
a small number of methylated CpG sites, we applied standard machine learning approaches. As for any 
statistical analysis, we partitioned the data by randomly selecting 70% (64 observations) of the individuals 
as the training set, and the remaining 30% (28 observations) as the testing set. Aiming to be 
representative, we maintained the cancer and healthy profile ratio of the original data in these training and 
testing sets. 
VARIABLE SCREENING 
                                                        
1 GEO dataset link: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89093. 
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Several methods were used to reduce the number of variables to a moderate range. We first computed 
the association between each CpG site and the response variable, then ranked the association from 
highest to lowest based on importance. This step includes four methods of variable screening: Pearson 
correlation, T-test, distance correlation, and expectation of conditional difference (ECD). From each 
method, we selected the 100 CpG sites with the highest ranking as potential candidates, and finally 
reported a subset of 55 common CpG sites across methods as our final choices (Figure 3). 
 
Figure 3. Variable Screen step. A: Sure Independence Screening; B: Independence Screening via 
Distance Correlation; C: T-test Analysis; D: Expectation of the Conditional Difference. Red line in 
the figure shows the first 100 variables according to the ranking of each approach. 
Sure Independence Screening. With the advent of modern technology for data collection, researchers 
are able to collect ultra-high dimensional data at relatively low cost in diverse fields of scientific research, 
such DNA methylation data. (Fan and Lv 2008) proposed the Sure Independence Screening (SIS) 
algorithm and shown that the Pearson correlation ranking procedure possesses a sure screening 
property. That is, all truly important predictors can be selected with a probability approaching one as the 
sample size diverges to infinity. We calculated the absolute value of the Pearson correlation between 
each predictor and response variable, as shown in Figure 4. We ordered the absolute values of Pearson 
correlation from high to low and picked the top 100 CpG sites (Figure 3A,). 
Independence screening via Distance Correlation. (Székely, Rizzo, and Bakirov 2007) proposed 
distance correlation and showed that the distance correlation of two random vectors equals zero if and 
only if these two random vectors are independent. Furthermore, the distance correlation of two univariate 
normal random variables is a strictly increasing function of the absolute value of the Pearson correlation 
of these two normal random variables. Li, Zhong and Zhu (2012) developed a sure independence 
screening procedure based on the distance correlation (DC-SIS), which is a model-free variable 
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screening algorithm that enjoys the sure screening property. We used it to calculate the distance 
correlation between each CpG site and the response variable. As shown in Figure 3B, we also ranked the 
distance correlation values from high to low and picked the top 100 CpG sites. 
T-test analysis. A T-test has long been considered the most direct analysis approach (Winer, Brown, and 
Michels 1971). For this study, we conducted an independent t-test to compare DNA methylation profiling 
in the cancer and healthy groups. CpG sites with smaller p-values indicate a higher difference between 
the two groups. We report the p-value and rank from lowest to highest in Figure 3C. 
ECD analysis. The expectation of conditional difference (ECD) is an independence measure developed 
by (Yin and Yuan, n.d.) that measures the association between two sets of random variables, especially 
when one of them is categorical or discrete. The measure is a value between 0 and 1; a higher value 
indicates a stronger association. We recorded the ECD measures and ranked them from highest to 
lowest, as shown in Figure 3D. 
MACHINE LEARNING ALGORITHMS 
We also implemented several machine learning algorithms using SAS® EM. These algorithms include 
Random Forest, Neural Network and Support Vector Machine (SVM), and their implementation pipeline is 
depicted in Figure 4. 
 
Figure 4. SAS® EM-generated implementation pipeline for Random Forest, Neural Network and 
Support Vector Machine algorithms. 
RESULTS 
After the variable screening step, we identified 55 common CpG sites among the top 100 candidates 
identified by each of the four different methods described above. We incorporated these 55 common CpG 
sites into our predictive model via Linear Discriminant Analysis of the training set. Model performance is 
reported in Table 1. Our algorithm reported a high accuracy of 71.4% on the testing set, and a false 
negative rate (FNR) of 14.3%. The false positive rate (FPR) is 42.9%; we believe this rate is acceptable, 
since the FNR is more important in clinical settings (Norris and Kahn, 2006). Our algorithm also reported 
a receiver operating characteristic (ROC) curve (Figure 4); the area under the curve (AUC) is 0.658. 
Data Set Accuracy FPR FNR 
 Training Set (70%)   100%   0%   0%  
 Testing Set (30%)   71.4%   42.9%   14.3%  
Table 1 Model performance (evaluation) summary. 
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Figure 4. Receiver operating characteristic (ROC) curve generated using linear discriminate analysis (LDA) 
for the testing dataset examining the 55 common CpG sites selected from the variable screening step. 
We also applied several different classification algorithms such as Random Forest, Neural Network and 
Support Vector Machine (SVM) provided from SAS® EM. Unfortunately, the performance of these 
algorithms was not desirable. With or without a variable screening step, these algorithms had an accuracy 
around 50%, the same rate expected for random guessing. Therefore, our simple statistical model 
algorithm outperformed these machine learning algorithms. 
To help other researchers understand our results, we decided to map the epigenetic CpG sites back to 
the genetic data. Since cancerous and healthy cells will have different methylation patterns (Feinberg & 
Vogelstein, 1983), important (high-ranked) CpG sites should correlate with the importance of genes. For 
the 55 CpG sites we identified 55 genes based on our mapping results. Among these 55 genes, the 
majority have unsurprisingly well-documented relationships with severe diseases including HIV-1, 
seizures from epilepsy, leukemia, and Basal Cell Nevus Syndrome, among others. Further, almost all of 
these genes have documented involvement in cancer development and progression. Table 2 provides a 
list of four interesting genes to demonstrate the correlation among CpG sites, genes and diseases; the full 
list of 55 genes can be found as supplementary data (refer to Supplement). 
CpG ID Associated 
Gene 
Gene Important/Function 
cg23412136 MIR548N Non-coding region (microRNAs), involved in post-transcriptional regulation of gene 
expression. 
cg09720012 PAPSS1 Diseases associated with PAPSS1 include Chronic Monocytic Leukemia. 
cg17964016 DEPTOR Inhibits the p53 kinase activity. 
cg16824024 PPP4R2 Related to pathways of DNA double-strand break repair. 
Table 2 Relation among CpG sites, associated genes and gene functions. 
Gene MIR548N (Table 2) is a pseudogene for microRNA (mRNA) that controlled by DNA methylation 
mechanism. This gene product, non-coding RNA molecule, inhibits and destabilizes a target mRNA; the 
consequences could include down-regulation of the relative gene expression. This gene has been 
reported as a potential biomarker and therapeutic target for nasopharyngeal carcinoma (Lee et al. 2016). 
Similarly, the PAPSS1 gene has been associated with chronic monocytic leukemia, and is reported to 
play an important role in cancer development (Leung et al. 2016). The DEPTOR gene inhibits p53 kinase 
activity and also appears to play an evolving role in tumor development and progression (Wang et al. 
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2012). Last but not least, the PPP4R2 gene is related to DNA repair, and has been implicated in a range 
of cancers (Bosio et al. 2012; Wu et al. 2016; Herzig and Bullinger 2016). 
DISCUSSION 
In this paper, we demonstrated the potential of methylation sites as measured in blood samples to serve 
as biomarkers for cancer. This approach could be a cheap alternative to many standard tests for cancer 
monitoring and early detection. One important limitation worth noting is the small sample size. The small 
sample size combined with a large number of features is a fundamental problem that hinders statistical 
analysis of health data. This can be illustrated from our results, in which we believe accuracy could be 
increased with a more balanced dataset and larger sample size. These features of the dataset are one 
reason we utilized an ensemble approach with 4 different methods for variable screening. The machine 
learning approaches, especially the neural network, did not perform well; however, when we consider that 
machine learning shines with big data, it’s not surprising it was less effective with this small dataset. We 
illustrated that when sample size is small, traditional statistical models utilizing SAS® Base can be a 
better solution than machine learning. 
There could be a smaller set of variables that could achieve same level of accuracy; therefore, we hope 
to apply other methods and further reduce the number of variables in future studies. One limitation of this 
study is the small sample size, i.e. the variable dimension is far larger than sample size. In this study, 
there were more than 450,000 variables, and the total sample size was only 92. To facilitate our future 
analysis, we would like to obtain a larger sample size. With more observations, the above-mentioned 
variable screening method and the follow up machine learning approaches will be more powerful to detect 
active predictors, and to better forecast the grouping of observations. In that way, our method should be 
able to differentiate specific cancer types within pan-cancer results, such as identifying breast, colon, or 
skin cancer in an individual. 
CONCLUSION 
In conclusion, we provide the first predictive model for pan-cancer using blood sample methylation 
profiling data. In this study, we identified 55 CpG sites and the associated genes that have the potential to 
serve as cancer biomarkers. Using profiling data from GSE89093 of methylation of 55 CpG sites, we built 
a classification model via linear discriminant analysis. This model allowed us to differentiate between 
cancer status (healthy/cancer) with high accuracy and low FNR. Other classification algorithms, such as 
generalized linear regression, SVM, random forest, and neural network, failed to perform well in the face 
of this ultra-high-dimensional problem with a small dataset. 
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SUPPLEMENT: 
CpG ID Associated 
Gene 
Gene Important/Function 
cg21330976   ANKRD29   Protein coding gene, an analog of this gene is associated with Urethral Diverticulum and Rectal Prolapse  
cg23412136   MIR548N   Non-coding region (microRNAs), involved in post-transcriptional regulation of gene expression.  
cg17383178   ZBED8   Protein coding gene. Related to nucleic acid binding.  
cg24382417  LOC100499489   RNA Gene, and is affiliated with the lncRNA class.  
cg20962444   DUSP22   Diseases associated include Alk-Negative Anaplastic Large Cell Lymphoma and Anaplastic Large Cell Lymphoma.  
cg23985331   ZFP36L2   Most likely functions in regulating the response to growth factors.  
cg02476348   EOMES   Function as transcription factor which is crucial for embryonic development of mesoderm and the central nervous system in vertebrates.  
cg13260133   BORCS7-ASMT   Epresents naturally occurring read-through transcription between the neighboring C10orf32 and AS3MT genes.  
cg03825236   RALGAPB   Telated pathways are Vesicle-mediated transport and Translocation of GLUT4 to the plasma membrane.  
cg02583183   CFDP1   May play a role during embryogenesis.  
cg03052760   ZMYM4   Diseases associated with ZMYM4 include Exudative Vitreoretinopathy 1 and Non-Syndromic X-Linked Intellectual Disability.  
cg13734860   EIF3E   Among its related pathways are p70S6K Signaling and Viral mRNA Translation.  
cg12733907   APPL1   Diseases associated with APPL1 include Maturity-Onset Diabetes Of The Young, Type 14 and Maturity-Onset Diabetes Of The Young.  
cg10362527   GPR1   May play a role for this receptor in the regulation of inflammation. Can act as a coreceptor for HIV-1.  
cg13560068   ZNF789   Function as sequence-specific DNA binding.  
cg02083376   EXT2   Diseases associated with EXT2 include Exostoses, Multiple, Type 2 and Seizures, Scoliosis, And Macrocephaly Syndrome. Among its related pathways 
are heparan sulfate.  
cg11287292   NEIL3   Function as initiate the first step in base excision repairing (DNA repairing)  
cg09720012   PAPSS1   Diseases associated with PAPSS1 include Chronic Monocytic Leukemia.  
cg20984590   KANSL2   May play a role in chromatin organization.  
cg17964016   DEPTOR   Inhibits the p53 kinase activity of both complexes.  
cg16824024   PPP4R2   Related pathways are DNA Double-Strand Break Repair.  
cg02741329   LSAMP  The encoded protein may also function as a tumor suppressor and may play a role in neuropsychiatric disorders. 
cg26103797   SAP18   Diseases associated with SAP18 include Basal Cell Nevus Syndrome.  
cg04774139   AVPR1A   Diseases associated with AVPR1A include Acth-Independent Macronodular Adrenal Hyperplasia and Asperger Syndrome.  
cg00046623   PXDNL   Diseases associated with PXDNL include Hypertrophy Of Breast.  
cg23978473   SLC22A23   Involves in transmembrane transporter activity.  
cg22467473   RHOBTB3   Involved in transport vesicle docking at the Golgi complex.  
cg25925896   RAB11B   Diseases associated with RAB11B include Rectum Adenocarcinoma and Cystic Fibrosis.  
cg11752893   TAP2   Diseases associated with TAP2 include  and .  
cg06216090   KLF3-AS1   An RNA Gene, and is affiliated with the non-coding RNA class.  
cg27559893   PRRC2A   Diseases associated with PRRC2A include  and .  
cg00257769   PARP4   Related pathways are  and .  
cg12176856   PDE8A   May be involved in maintaining basal levels of the cyclic nucleotide and/or in the cAMP regulation of germ cell development.  
cg25513659   RPH3AL   Rab GTPase effector involved in the late steps of regulated exocytosis, both in endocrine and exocrine cells (By similarity). Diseases associated with 
RPH3AL include .  
cg15416250   CEP128    
cg18363143   LINC01588   RNA Gene, and is affiliated with the non-coding RNA class.  
cg16859636   PRR26   RNA Gene, and is affiliated with the ncRNA class.  
cg12799677   ALDH9A1   Diseases associated with ALDH9A1 include  and . Among its related pathways are  and .  
cg27482690   TNRC18   This gene involves chromatin binding and transcription regulatory region sequence-specific DNA binding.  
cg24926589   CERKL   Diseases associated with CERKL include  and .  
cg06254123   NDE1   Diseases associated with NDUFS7 include  and .  
cg00774300   TSFM   Diseases associated with TSFM include  and .  
cg01358940   LINC01164   RNA Gene, and is affiliated with the non-coding RNA class.  
cg04825119   AQP6   The protein encoded by this gene is an aquaporin protein, which functions as a water channel in cells.  
cg13384284   LINC00693   This gene encodes a member of the neuronal calcium sensor (NCS) family of calcium-binding proteins.  
cg27637873   NCALD   This gene encodes a member of the neuronal calcium sensor (NCS) family of calcium-binding proteins.  
cg00188298   ENTPD1-AS1   RNA Gene, and is affiliated with the non-coding RNA class.  
cg15080870   CCDC9   Involves poly(A) RNA binding.  
cg10083046   UBE4A   The encoded protein is involved in multiubiquitin chain assembly and plays a critical role in chromosome condensation and separation through the 
polyubiquitination of securin. Autoantibodies against the encoded protein may be markers for scleroderma and Crohn's disease.  
cg10500503   PLPP3   Diseases associated with PLPP3 include .  
cg22113065   COL4A3BP   Diseases associated with COL4A3BP include  and .  
cg15592324   TAF4B   Diseases associated with TAF4B include . Among its related pathways are  and .  
cg09726509   SLC43A1   Diseases associated with SLC43A1 include .  
cg27351449   AHI1   Diseases associated with AHI1 include  and .  
cg11598353   NDUFS7   Diseases associated with NDUFS7 include  and .  
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